Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Recurrent Mycosis Fungoides: early-phase trial registry

3 of 7 indexed Recurrent Mycosis Fungoides trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,497 of 28,707 conditions by registered trial count.

7 US clinical trials · 3 currently recruiting · #2,497 of 28,707 conditions by registered trial count

Recurrent Mycosis Fungoides: 7 US clinical trials tracked, 3 recruiting.

Recurrent Mycosis Fungoides is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is City of Hope Medical Center, running 3 of these trials.

Enrollment posture brief

Registry condition recurrent-mycosis-fungoides

OPEN 3 | RECR 43% | LATE 0 | EARLY 5 | RANK #2497 | SPON 3

Nearest open-share peer: Adrenoleukodystrophy (43% recruiting · 7 trials)

ACL Tear71.4%ACL57.1%Recurrent Mycosis Fungoi (th…43%Acute Myelogenous Leukemia42.9%Acne Scars28.6%
Open-enrollment share among volume-matched conditions near Recurrent Mycosis Fungoides

Recurrent Mycosis Fungoides lists 3 open slots (43% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Recurrent Mycosis Fungoides on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Recurrent Mycosis Fungoides is recruiting below its size-band peers.

    3 of 7 indexed trials (42.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Recurrent Mycosis Fungoides research.

    City of Hope Medical Center accounts for 3 of 7 trials (42.9%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Most Recurrent Mycosis Fungoides trials plan to enrol fewer than 100 people.

    Median target enrolment is 39 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.

  4. Recurrent Mycosis Fungoides research is mostly interventional.

    5 interventional and 2 observational studies make up this index (71.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 15

Open and recent trials

7 total, page 1 of 1

RECRUITING Phase 1 127 participants

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Mayo Clinic

NCT03017820

RECRUITING 100 participants

A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab

City of Hope Medical Center

NCT07003100

RECRUITING 60 participants

Low-Dose Total Skin Electron Therapy in Treating Patients With Refractory or Relapsed Stage IB-IIIA Mycosis Fungoides

Vanderbilt-Ingram Cancer Center

NCT02702310

ACTIVE NOT RECRUITING Phase 1 39 participants

Study of Pembrolizumab (MK-3475) in Combination With Romidepsin

M.D. Anderson Cancer Center

NCT03278782

ACTIVE NOT RECRUITING Phase 1 38 participants

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

City of Hope Medical Center

NCT03011814

ACTIVE NOT RECRUITING Phase 1 21 participants

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

National Cancer Institute (NCI)

NCT02520791

ACTIVE NOT RECRUITING Phase 1 13 participants

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

City of Hope Medical Center

NCT03598998

Phase Distribution

PhaseTrial count
Phase 1 5

Named interventions

Most-linked intervention names on Recurrent Mycosis Fungoides records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Laboratory Biomarker Analysis Other
2 trials
Pembrolizumab Biological
2 trials
Anti-ICOS Monoclonal Antibody MEDI-570 Biological
1 trials
Pharmacological Study Other
1 trials
Objective Grading of Skin Findings Other
1 trials
Romidepsin Drug
1 trials
Pralatrexate Drug
1 trials
Lenalidomide Drug
1 trials

US sites by state

Facility locations filed on Recurrent Mycosis Fungoides trials. A trial with sites in several states counts in each.

Texas 4 trials
California 4 trials
Pennsylvania 2 trials
New York 2 trials
Nebraska 2 trials
Missouri 2 trials
Georgia 2 trials
Florida 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Recurrent Mycosis Fungoides page

7 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Mycosis Fungoides condition card totals 7 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.